Antimicrobial susceptibility of Stenotrophomonas maltophilia from United States medical centers (2019-2023).

Abstract

We evaluated the antimicrobial susceptibility of 1,400 clinical isolates of Stenotrophomonas maltophilia consecutively collected from United States medical centers in 2019-2023. Aztreonam-avibactam (MIC_50/90, 2/4 µg/mL; 99.6% inhibited at ≤8 µg/mL) was the most active compound, followed by trimethoprim-sulfamethoxazole (MIC_50/90, ≤0.12/0.5 µg/mL; 96.9% susceptible), minocycline (MIC_50/90, 0.5/2 µg/mL; 89.2% susceptible), and levofloxacin (MIC_50/90, 1/8 µg/mL; 78.9% susceptible). Aztreonam-avibactam retained potent activity against isolates not susceptible to trimethoprim-sulfamethoxazole, minocycline, and/or levofloxacin (99.3%-100.0% inhibited at ≤8 µg/mL).